Search - tctmd.com

Displaying 21 - 40 of 144

Sort: Relevancy | Date

Presentation TCT 2024

TCT 364: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions: 5 Clinical Year Outcomes

Presenter: Matthias Lutz

October 27, 2024

Presentation EuroPCR 2024

Patient and procedure characteristics for 1000 Selution SLRTM sirolimus-eluting balloon procedures

Presenter: Simon Eccleshall

May 14, 2024

Presentation EuroPCR 2024

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

Presenter: Alexandre Abizaid

May 14, 2024

Presentation TCT 2023

TCT 418: Impact of diabetes on clinical outcomes after percutaneous coronary intervention: 5-year results of the SORTOUT IX trial comparing the polymer-free biolimus A9-coated stent to the ultra-thin strut biodegradable polymer sirolimus-eluting stent

Presenter: Kirstine Hansen

October 25, 2023

Presentation TCT 2023

TCT 522: Ultrathin Strut Biodegradable Polymer-coated Sirolimus-eluting Stents in an All-comers Patient Population – The Prospective S-FLEX UK-II Registry

Presenter: Azfar Zaman

October 25, 2023

Presentation TCT 2023

TCT 708: Five-Year Outcomes of Patients With Diabetes Mellitus Treated With a Sirolimus-Eluting or a Biolimus-Eluting Stents With Biodegradable Polymer. From the SORT OUT VII Trial

Presenter: Jens Trøan

October 25, 2023

Presentation TCT 2023

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

Presenter: Juan Iglesias

October 25, 2023

Presentation TCT 2023

TCT 761: Sirolimus Eluting, Tyrocore, Bioresorbable Vascular Scaffold Implantation in Patients with ST Segment Elevation Myocardial Infarction: 18 Month Outcomes – FANTOM STEMI Pilot Study

Presenter: Lukasz Koltowski

October 25, 2023

Presentation TCT 2023

TCT 575: Post Market Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold – 24 Month Clinical Outcomes in First 100 Patients

Presenter: Matthias Lutz

October 25, 2023

Presentation TCT 2023

TCT 497: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 4 Clinical Year Outcomes

Presenter: Matthias Lutz

October 25, 2023

Presentation TCT 2023

TCT 591: Preclinical Evaluation of a Novel Bioresorbable Sirolimus Eluting Magnesium-Alloy Scaffold in a Healthy Swine Coronary Arteries up to 540 Days

Presenter: Sho Torii

October 25, 2023

Presentation TCT 2023

TCT 576: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final 5 Year Clinical Outcomes

Presenter: Matthias Lutz

October 25, 2023

TCT 669: Impact of ACS on Long-Term Clinical Outcomes After PCI With the Biolimus-Coated BioFreedom Stent or Biodegradable Polymer Sirolimus-Eluting Orsiro Stent: From the SORT OUT IX Trial

Presentation TCT 2023

TCT 669: Impact of Acute Coronary Syndromes on Long-Term Clinical Outcomes After Percutaneous Coronary Intervention With the Biolimus-Coated BioFreedom Stent or Biodegradable Polymer Sirolimus-Eluting Orsiro Stent: From the SORT OUT IX Trial

Presenter: Manijeh Noori

October 24, 2023

Presentation EuroPCR 2023

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

Presenter: Shigeru Saito

May 18, 2023

Presentation TCT 2022

Safety and Performance of a Sirolimus Eluting Resorbable Coronary Magnesium Scaffold (DREAMS 3G): The BIOMAG-1 FIH Trial

Presenter: Michael Haude

September 19, 2022

Presentation TCT 2022

TCT 155: The Bioadaptor RCT Study: Comparison of a Novel Sirolimus-Eluting Bioadaptor with Zotarolimus-Eluting Stent in de novo Coronary Arteries

Presenter: Holger Nef

September 19, 2022

Presentation TCT 2022

TCT 64: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 3 Clinical Year Outcomes

Presenter: Matthias Lutz

September 17, 2022

Presentation TCT 2022

TCT 58: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final: 5 Year Clinical Outcomes

Presenter: Matthias Lutz

September 17, 2022

Presentation TCT 2021

A Novel Sirolimus-Eluting Iron-Based Bioresorbable Scaffold Implantation in Single De Novo Coronary Lesions: Two-Year Clinical and Imaging Outcomes from the First in Man Study (IBS-FIM)

Presenter: Runlin Gao

November 05, 2021

Presentation TCT 2021

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Presenter: Matthias Lutz

November 04, 2021

Advertisement

TCT 364: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions: 5 Clinical Year Outcomes

Patient and procedure characteristics for 1000 Selution SLRTM sirolimus-eluting balloon procedures

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

TCT 418: Impact of diabetes on clinical outcomes after percutaneous coronary intervention: 5-year results of the SORTOUT IX trial comparing the polymer-free biolimus A9-coated stent to the ultra-thin strut biodegradable polymer sirolimus-eluting stent

TCT 522: Ultrathin Strut Biodegradable Polymer-coated Sirolimus-eluting Stents in an All-comers Patient Population – The Prospective S-FLEX UK-II Registry

TCT 708: Five-Year Outcomes of Patients With Diabetes Mellitus Treated With a Sirolimus-Eluting or a Biolimus-Eluting Stents With Biodegradable Polymer. From the SORT OUT VII Trial

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

TCT 761: Sirolimus Eluting, Tyrocore, Bioresorbable Vascular Scaffold Implantation in Patients with ST Segment Elevation Myocardial Infarction: 18 Month Outcomes – FANTOM STEMI Pilot Study

TCT 575: Post Market Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold – 24 Month Clinical Outcomes in First 100 Patients

TCT 497: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 4 Clinical Year Outcomes

TCT 591: Preclinical Evaluation of a Novel Bioresorbable Sirolimus Eluting Magnesium-Alloy Scaffold in a Healthy Swine Coronary Arteries up to 540 Days

TCT 576: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final 5 Year Clinical Outcomes

TCT 669: Impact of Acute Coronary Syndromes on Long-Term Clinical Outcomes After Percutaneous Coronary Intervention With the Biolimus-Coated BioFreedom Stent or Biodegradable Polymer Sirolimus-Eluting Orsiro Stent: From the SORT OUT IX Trial

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

Safety and Performance of a Sirolimus Eluting Resorbable Coronary Magnesium Scaffold (DREAMS 3G): The BIOMAG-1 FIH Trial

TCT 155: The Bioadaptor RCT Study: Comparison of a Novel Sirolimus-Eluting Bioadaptor with Zotarolimus-Eluting Stent in de novo Coronary Arteries

TCT 64: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 3 Clinical Year Outcomes

TCT 58: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final: 5 Year Clinical Outcomes

A Novel Sirolimus-Eluting Iron-Based Bioresorbable Scaffold Implantation in Single De Novo Coronary Lesions: Two-Year Clinical and Imaging Outcomes from the First in Man Study (IBS-FIM)

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content